Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

Published on July 15, 2014 at 9:14 AM · No Comments

The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer). For eligible patients the positive impact of Metvix PDT cannot be overestimated in pre-cancerous AK (Actinic Keratoses) and superficial BCC (Basal Cell Carcinomas) treatment.

Metvix PDT delivers precisely targeted treatment for AK and BCC. Metvix PDT is changing the treatment of AK and BCC by offering patient preferred advantages:

  • Clinical outcomes comparable to current standard modes of treatment
  • Minimally non-invasive procedure with superior cosmetic outcomes
  • Healing can take place in as little as 7-10 days as treatment is precisely directed

The Odette Cancer Centre, one of the top cancer centres in the world, consistently offers the highest level of patient care while conducting world-class research and teaching in a clinical setting. Always committed to improving treatment and patient care, the Odette Cancer Centre once again leads the way by offering Metvix PDT for NMSC. Instrumental in bringing Metvix PDT to the Centre Dr. Gregory Czarnota, senior scientist & director, Odette Cancer Research Program, Dr. Steven Babic, medical physicist, and Dr. Toni Barnes, radiation oncologist are at the forefront of this initiative that marks a new area of NMSC treatment.

The Odette Cancer Centre is ranked the 2nd largest comprehensive cancer centre in Canada and the 6th largest comprehensive cancer centre in North America, ranked among a select group of world-class institutions who engage in intense research, community outreach and who provide the full spectrum of patient care.

The partnership of Galderma and the Odette Cancer Centre reinforces the strong commitment of both parties to continue to bring the most innovative and technologically advanced treatments to improve patients' experiences and outcomes when being treated for AK and NMSC.

Source:

Galderma Canada Inc.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Majority of states not measuring up on legislative solutions that fight cancer, shows report